Anastrozole — reference
Non-steroidal aromatase inhibitor; approved for hormone-receptor-positive breast cancer, used off-label to control estradiol during testosterone therapy.
Regulatory status
FDA-Approved (labeled use). FDA-approved for breast cancer. Use in men to manage estradiol is off-label and not an approved indication.
Reported cautions
Pharmacokinetics
Published figures give an elimination half-life of ~46–50 hours. FDA label (Arimidex).
This figure is tagged FDA label in our evidence system. This figure appears in an approved product's prescribing information, which is the strongest tier in our system — a regulator-reviewed number for a specific approved product. You can see the shape this implies between doses in the Half-Life Visualizer, and compare it against every other compound in the Half-Life Data Table. Our sourcing page explains what each tier means.
Remember that an estimated curve is a model built from a population figure, not a measurement of your blood. Individual clearance varies, and for depot injections the figure describes release from the injection site rather than the compound clearing. Half-life explained →
What Peptide Plug does and does not publish
This page carries regulatory status, general context and published pharmacokinetics. It carries no dose, frequency or cycle information — that is a deliberate editorial line, because dosing is a clinical decision rather than reference data. We also do not sell, supply, source or link to vendors for any compound.
Frequently asked
Is Anastrozole FDA-approved?
What is the half-life of Anastrozole?
How reliable is that half-life figure?
What cautions are associated with Anastrozole?
Does Peptide Plug publish dosing for Anastrozole?
Does Peptide Plug sell Anastrozole?
Related tools
Free, no account required.